TG Therapeutics, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. The company is a development-stage biopharmaceutical business developing TG-1101 (ublituximab) and TGR-1202 for hematologic malignancies. It had no approved products and no product-sale revenue.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| License revenue | $38,095 | $38,095 |
| Research and development expense | $4.41 million | $1.57 million |
| General and administrative expense | $3.23 million | $2.18 million |
| Total costs and expenses | $7.64 million | $3.75 million |
| Operating loss | $7.61 million | $3.71 million |
| Net loss | $7.55 million, or $0.25 per share | $3.67 million, or $0.17 per share |
| Cash used in operating activities | $8.33 million | $2.20 million |
Revenue was the amortization of the $2.0 million Ildong sublicense upfront payment; the filing reports no commercial product revenue. The company recorded $4.23 million of stock-based compensation in Q1 2014, up from $1.89 million, primarily due to milestone-based restricted-stock vesting. Research and development spending rose with increased clinical-trial enrollment; management expected those costs to increase modestly for the rest of 2014. No meaningful operating margin is presented for this development-stage business.
At March 31, 2014, cash and cash equivalents were $49.60 million, investment securities totaled $4.90 million, and interest receivable was $11,124. Together these were approximately $54.51 million. Total assets were $58.17 million; current liabilities were $1.99 million; total liabilities were $3.74 million; and equity was $54.43 million. Accumulated deficit was $46.95 million.
March financing included a public offering of 2,702,809 common shares. Net proceeds were approximately $16.8 million; the quarter also included $901,472 from warrant exercises. Net cash provided by financing activities was $17.44 million. Cash and cash equivalents increased by $9.11 million during the quarter.
Material changes and unusual items
- Net loss more than doubled year over year, mainly as research and development and noncash compensation expenses increased.
- The March public offering increased shares issued; 37,624,407 common shares were outstanding on May 1, 2014.
- The company settled its defaulted ICON note in January 2014, agreeing to pay $772,369 in full settlement of principal and interest and recording a $95,427 gain. The balance sheet no longer showed the ICON note at quarter-end.
- The remaining 5% notes had a $115,554 fair-value carrying amount at March 31, 2014. The filing also reports $18.84 million of face principal and accrued interest; the company states its obligations are tied to specified legacy-product cash flows and the conversion feature, and no payments had been made.
- Deferred revenue under the Ildong agreement was approximately $1.79 million at quarter-end. The agreement may provide up to a further $5.0 million in milestone payments and royalties if TG-1101 is commercialized in the licensed territories.
Outlook, commentary and risks
Management estimated that March 31 cash and cash equivalents would fund anticipated operating requirements for at least 24 months. It also stated that future financing would be needed to execute its plans, and that actual cash needs depend in part on clinical-trial timing, design and conduct. The company expected continued operating losses and said it might never become profitable.
Clinical programs described include TG-1101 combinations with ibrutinib and TGR-1202, and a TGR-1202 Phase I study. The filing reports preliminary tolerability observations, not definitive evidence of safety or efficacy. It describes post-quarter developments as well: enrollment in the TG-1101 single-agent study had completed by May 2014, and a micronized TGR-1202 formulation showed improved absorption in healthy-human testing; dose escalation was restarted using the new formulation. These are development updates, not regulatory approvals or established clinical benefit.
Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on licensors and third-party manufacturers and service providers, competition, intellectual-property challenges, and the need for additional capital. Management reported effective disclosure controls as of March 31, 2014, no material change in internal control over financial reporting, and no material pending legal proceedings.
Investor verification points
- Confirm the cash runway assumptions against subsequent trial costs, enrollment and financing needs.
- Track clinical data and regulatory progress for both candidates, including results from combination studies and the revised TGR-1202 formulation.
- Review the 5% notes’ terms, fair-value assumptions and contingent payment obligations; distinguish their carrying value from reported face principal and accrued interest.
- Assess dilution from equity offerings, warrant exercises and outstanding equity awards, including any further use of the shelf registration statement.
- Monitor Ildong milestone and royalty conditions, deferred-revenue recognition, and whether any product achieves approval or commercial sales.